Fig. S1. Multiple myeloma clinical trial design. Previously untreated newly diagnosed patients were enrolled onto the Litvacc study (a), where following lenalidomide + dexamethasone (LEN + DEX) induction the patients received an autologous stem cell transplantation (ASCT) followed by myeloma lysate-pulsed dendritic cells (DCs) + LEN maintenance or len maintenance alone (in our study, 10 of 11 patients received myeloma lysate-pulsed DCs + LEN maintenance). Patients with refractory relapsed disease were enrolled into the RevLite study (b) to receive LEN + DEX induction, then repeated cycles of LEN + DEX until disease progression. A comparison between the two trials is provided in table (c) including disease state, drug dose and cycles of therapy.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.